Khurram Rana, PharmD

Sr. Director
Innoviva Specialty Therapeutics
Madison, Connecticut, United States

Disclosure information not submitted.

Presentation(s):

• 646 - Subgroup Analyses of Microbiological Cure Rates by Baseline Zoliflodacin MIC and Susceptibility to Ciprofloxacin in Participants from the Global Zoliflodacin Phase 3 Randomized Controlled Trial

  Wednesday, October 22, 2025
  2:45 PM - 2:57 PM US ET